HomeCompareCLZNY vs JNJ

CLZNY vs JNJ: Dividend Comparison 2026

CLZNY yields 5.21% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $9.7K in total portfolio value· pulled ahead in Year 6
10 years
CLZNY
CLZNY
● Live price
5.21%
Share price
$9.85
Annual div
$0.51
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$0.53
Full CLZNY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CLZNY vs JNJ

📍 JNJ pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLZNYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLZNY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLZNY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLZNY
Annual income on $10K today (after 15% tax)
$442.69/yr
After 10yr DRIP, annual income (after tax)
$0.45/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,985.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLZNY + JNJ for your $10,000?

CLZNY: 50%JNJ: 50%
100% JNJ50/50100% CLZNY
Portfolio after 10yr
$25.4K
Annual income
$2,344.97/yr
Blended yield
9.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CLZNY
Analyst Ratings
4
Buy
2
Hold
Consensus: Buy
Altman Z
3.0
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLZNY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLZNYJNJ
Forward yield5.21%2.13%
Annual dividend / share$0.51$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$20.6K$30.3K
Annual income after 10y$0.53$4,689.40
Total dividends collected$529.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CLZNY vs JNJ ($10,000, DRIP)

YearCLZNY PortfolioCLZNY Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,960$260.41$10,592$272.30+$368.00CLZNY
2$11,861$133.37$11,289$357.73+$572.00CLZNY
3$12,759$67.44$12,123$472.89+$636.00CLZNY
4$13,686$33.90$13,141$629.86+$545.00CLZNY
5$14,661$16.99$14,408$846.81+$253.00CLZNY
6← crossover$15,695$8.51$16,021$1,151.60$326.00JNJ
7$16,798$4.26$18,122$1,588.22$1.3KJNJ
8$17,976$2.13$20,930$2,228.20$3.0KJNJ
9$19,236$1.06$24,792$3,191.91$5.6KJNJ
10$20,583$0.53$30,274$4,689.40$9.7KJNJ

CLZNY vs JNJ: Complete Analysis 2026

CLZNYStock

Clariant AG operates as a specialty chemical company worldwide. It operates through three segments: Care Chemicals, Catalysis, Natural Resources. The company offers flame retardants, performance additives, and advanced surface solutions for use in plastics, coatings, inks, and consumer applications; and catalysts for the petrochemical and fuel refining, synthesis gas, chemical, emissions control, specialty zeolites and zeolite-based, and custom catalyst markets. It also provides bentonite-based specialty products for the oil purification, foundry additive, feed additives, civil engineering, wastewater treatment, clay specialties, paper and detergent additive, PVC stabilizer, BTX-catalyst, and kerosene and jet fuel purification industries. In addition, the company offers industrial and consumer specialty chemicals and application solutions for the automotive brake fluid and coolant, aircraft anti-itching and deicing fluid, construction chemical, agrochemical and agricultural adjuvants, food ingredients, gas treatment, heat transfer fluid, home care, industrial cleaning, industrial lubricant additive, special solvent, paint and coating, healthcare, and personal care ingredient markets. Further, it offers oilfield production chemicals for enhanced oil recovery, offshore and deep water, conventional and unconventional oil and gas, heavy oil, paraffin control technologies, and well services additives, as well as Veritrax, an intelligent chemical management system; chemical solutions for the end-to-end mining process; refinery services' additives; biofuels and derivatives, such as sunliquid, an agricultural residue converted to cellulosic ethanol; and organic, inorganic, and anti-corrosive pigments, as well as pigment preparations, dyes, and specialty material for use in coatings, plastics, printing and digital printing, home, fabric, personal care, and other applications. Clariant AG was founded in 1886 and is headquartered in Muttenz, Switzerland.

Full CLZNY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CLZNY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLZNY vs SCHDCLZNY vs JEPICLZNY vs OCLZNY vs KOCLZNY vs MAINCLZNY vs ABBVCLZNY vs MRKCLZNY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.